Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure

被引:14
作者
Newton, P
Keeratithakul, D
Teja-Isavadharm, P
Pukrittayakamee, S
Kyle, D
White, N
机构
[1] Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand
[2] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Dis, Oxford, England
[3] Armed Forces Res Inst Med Sci, Dept Immunol & Parasit, USA Med Component, Bangkok, Thailand
基金
英国惠康基金;
关键词
malaria; Plasmodium falciparum; renal failure; chemotherapy; quinine; 3-hydroxyquinine; pharmacokinetics; Thailand;
D O I
10.1016/S0035-9203(99)90184-0
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The plasma concentrations of quinine and its main metabolite, 3-hydroxyquinine (3OHQn), were measured in 5 adult Thai patients with severe Plasmodium falciparum malaria and acute renal failure. Two patients required peritoneal dialysis but all survived. During acute renal failure plasma concentrations of 3OHQn rose to reach up to 45% of the levels of the parent compound. The estimated median (range) quinine clearance was 0.83 mL/kg/min (0.58-1.16), and 3OHQn clearance/fraction of quinine converted was 3.40 mL/kg/min (2.58-4.47). The estimated 3OHQn terminal elimination half-life was 21 h (16.5-32.5). These data suggest that 3OHQn contributes about 12% of the antimalarial activity of the parent compound in patients with falciparum malaria and acute renal failure. It is also likely that 3OHQn contributes to adverse effects, although this metabolite is not quantitated routinely by current high-performance liquid chromatography quinine assays.
引用
收藏
页码:69 / 72
页数:4
相关论文
共 10 条
[1]   SIMULTANEOUS MEASUREMENT OF QUININE AND QUINIDINE IN HUMAN PLASMA, WHOLE-BLOOD, AND ERYTHROCYTES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION [J].
EDSTEIN, MD ;
PRASITTHIPAYONG, A ;
SABCHAREON, A ;
CHONGSUPHAJAISIDDHI, T ;
WEBSTER, HK .
THERAPEUTIC DRUG MONITORING, 1990, 12 (05) :493-500
[2]   Pharmacokinetics of quinine, chloroquine and amodiaquine - Clinical implications [J].
Krishna, S ;
White, NJ .
CLINICAL PHARMACOKINETICS, 1996, 30 (04) :263-299
[3]   Antimalarial activity and interactions between quinine, dihydroquinine and 3-hydroxyquinine against Plasmodium falciparum in vitro [J].
Nontprasert, A ;
Pukrittayakamee, S ;
Kyle, DE ;
Vanijanonta, S ;
White, NJ .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1996, 90 (05) :553-555
[4]   A study of the factors affecting the metabolic clearance of quinine in malaria [J].
Pukrittayakamee, S ;
Looareesuwan, S ;
Keeratithakul, D ;
Davis, TME ;
TejaIsavadharm, P ;
Nagachinta, B ;
Weber, A ;
Smith, AL ;
Kyle, D ;
White, NJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (06) :487-493
[5]   PHARMACODYNAMICS OF 3-HYDROXYQUINIDINE ALONE AND IN COMBINATION WITH QUINIDINE IN HEALTHY-PERSONS [J].
VOZEH, S ;
BINDSCHEDLER, M ;
HA, HR ;
KAUFMANN, G ;
GUENTERT, TW ;
FOLLATH, F .
AMERICAN JOURNAL OF CARDIOLOGY, 1987, 59 (06) :681-684
[6]  
WHITE NJ, 1983, AM J TROP MED HYG, V32, P1
[7]  
WHITE NJ, 1992, BRIT J CLIN PHARMACO, V34, P1
[8]   QUININE PHARMACOKINETICS AND TOXICITY IN CEREBRAL AND UNCOMPLICATED FALCIPARUM-MALARIA [J].
WHITE, NJ ;
LOOAREESUWAN, S ;
WARRELL, DA ;
WARRELL, MJ ;
BUNNAG, D ;
HARINASUTA, T .
AMERICAN JOURNAL OF MEDICINE, 1982, 73 (04) :564-572
[9]  
Zhao XJ, 1996, J PHARMACOL EXP THER, V279, P1327
[10]  
[No title captured]